A Single-Center, Double-Blind, Placebo-Controlled, Phase 1A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sequential Dose Regimens of Oral EC5026 in Healthy Male and Female Subjects
Phase: PHASE1
Conditions: Healthy Adults
Sponsor: EicOsis Human Health Inc.

Sponsor: 
Sponsor Contact: 
Medical Monitors: 
Version of Protocol: 
Date of Protocol: 
CLINICAL STUDY PROTOCOL 
IND 142,184 
NCT04228302
A SINGLE-CENTER, DOUBLE-BLIND, PLACEBO-
CONTROLLED, PHASE lA SINGLE ASCENDING DOSE STUDY 
TO INVESTIGATE THE SAFETY, TOLERABILITY, AND 
PHARMACOKINETICS OF SEQUENTIAL DOSE REGIMENS OF 
ORAL EC5026 IN HEALTHY MALE AND FEMALE SUBJECTS 
PROTOCOL NO. EC5026-1-01 
EicOsis Human Health, Inc. 
140 B Street 
Suite 5, Number 346 
Davis, CA 95616 
2.0 
15 October 2019 
CONFIDENTIAL 
The concepts and information contained in this document or generated during the study are 
considered proprietary and may not be disclosed in whole or in part without the expressed, 
written consent of EicOsis Human Health, Inc. 
The study will be conducted according to the International Council for Harmonisation 
Guideline E6(R2): Good Clinical Practice.